Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 earnings results
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q3 2026 results on Nov 3, 2026, 8:08:58 AM ET: GAAP EPS $1.83 vs. -$1.09 expected (beat by $2.92); revenue $431.30M vs. $405.12M expected (beat by 6.5%). Outlook: The addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $1.83 | -$1.09 | Beat by $2.92 |
| Revenue | $431.30M | $405.12M | Beat by 6.5% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 3, 2026, 8:08:58 AM ET. Nexqual published them 41 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 50.1% from $287.27M; GAAP diluted EPS was $1.83 vs. -$4.01.
Stock reaction
The results came out before the market opened. MDGL closed at $396.32 on November 3, 2026, down 8.1% from its $431.16 close on November 2, 2026 before the results.
Questions and answers
Did Madrigal Pharmaceuticals, Inc. beat earnings expectations?
Yes. Madrigal Pharmaceuticals, Inc. reported GAAP EPS of $1.83 against an average analyst estimate of -$1.09 (beat by $2.92), and revenue of $431.30M against $405.12M expected (beat by 6.5%).
What were Madrigal Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $1.83 and revenue of $431.30M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 50.1% from $287.27M; GAAP diluted EPS was $1.83 vs. -$4.01.
When did Madrigal Pharmaceuticals, Inc. report Q3 2026 earnings?
Nov 3, 2026, 8:08:58 AM ET, in an SEC 8-K filing (Item 2.02).
How did MDGL stock react to the earnings?
The results came out before the market opened. MDGL closed at $396.32 on November 3, 2026, down 8.1% from its $431.16 close on November 2, 2026 before the results.
What did Madrigal Pharmaceuticals, Inc. say about its outlook?
The addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026.
More on MDGL
MDGL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 3, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 4, 2026 at 10:47 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 4, 2026 at 10:47 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt